Access Agreement Could Benefit Clinicians and Patients

Diagnostics solution provider Arcis Biotechnology has signed a technology access agreement allowing Teflex Inc access to its advanced nucleic acid sample preparation chemistry. The New York-based company will harness the tecnology in the development of a novel technology, which it believes will be disruptive and is intended to empower clinicians and drive better patient outcomes.

Offering the possibility of earlier diagnostics testing from a variety of sample types, the platform, which covers DNA and RNA extraction and preservation for downstream processing, was said to be supportive of both companies’ drive to improve diagnostic testing and benefit patients and healthcare professionals.

Peter Whitehurst, CEO, Arcis Biotechnology, commented: “We are delighted that Teleflex has chosen to leverage the speed and simplicity of our sample preparation technology in its product development programme. Obtaining genetic material from biological samples is a critical step in molecular biology processes and we are excited to see our platform being applied across many different and growing markets.”

The company recently announced a successful £1.25 million investment round and additional £0.5 million overfunding hosted by crowdfunding platform Capital Cell, following following its development successes in the isolation and preservation of microRNA (miRNA) and oncology biomarkers. Arcis is now looking to invest further in R&D and product development to drive international business expansion. The additional £0.5 million from the Capital Cell funding round will underpin the Company’s projected revenue growth and associated working capital requirements in the next two years.